Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase 2 KEYNOTE-224 trial

医学 耐受性 彭布罗利珠单抗 队列 内科学 索拉非尼 不利影响 临床终点 实体瘤疗效评价标准 肝细胞癌 耐火材料(行星科学) 外科 四分位间距 胃肠病学 肿瘤科
作者
Gontran Verset,Ivan Borbath,Mark Karwal,Chris Verslype,Hans Van Vlierberghe,Adel Kardosh,Vittorina Zagonel,Per Stål,Debashis Sarker,Daniel H Palmer,Arndt Vogel,Julien Edeline,Stephane Cattan,Masatoshi Kudo,Ann Li Cheng,Sadahisa Ogasawara,Bruno Daniele,Stephen L Chan,Jennifer J Knox,Shu-Kui Qin,Abby B Siegel,Michael Chisamore,Ken Hatogai,Anran Wang,Richard S. Finn,Andrew X. Zhu
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
标识
DOI:10.1158/1078-0432.ccr-21-3807
摘要

Abstract Purpose:KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with aHCC and no prior systemic therapy. Experimental Design:KEYNOTE-224 was an open-label, multi-country phase 2 trial. Eligible patients in cohort 2 had aHCC not amenable or refractory to locoregional therapy and not previously treated with systemic therapy. Patients received pembrolizumab 200 mg intravenously every three weeks for {less than or equal to}2 years. Primary endpoint was objective response rate (ORR) by central imaging review per RECIST v1.1. Secondary endpoints included duration of response (DOR), disease control rate (DCR), time to progression (TTP), progression-free survival (PFS), overall survival (OS), and safety/tolerability. Results: Between Sept 4, 2018 and Feb 20, 2019, 51 patients were allocated in cohort 2. The median time from the first dose to data cutoff (Jan 19, 2021) was 27 months (range, 23-29). ORR was 16% (95% CI, 7-29) and was similar across key subgroups. Median DOR was 16 months (range, 3-24+), and DCR was 57%. The median PFS was 4 months (95% CI, 2-8), and median TTP was 4 months (95% CI, 3-9). Median OS was 17 months (95% CI, 8-23). Grade {greater than or equal to}3 treatment-related adverse events occurred in 16% of patients. Conclusions:In patients with aHCC with no prior systemic therapy, pembrolizumab provided durable antitumor activity, promising OS, and had a safety profile consistent with previous observations. These findings support further evaluation of pembrolizumab-based regimens for HCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
忧郁荔枝完成签到 ,获得积分20
刚刚
morena应助禾盒采纳,获得80
1秒前
2428完成签到,获得积分10
2秒前
阿静完成签到,获得积分20
2秒前
是瓜瓜不发布了新的文献求助20
2秒前
大个应助清爽的凤采纳,获得10
3秒前
3秒前
cometx发布了新的文献求助10
3秒前
hang完成签到,获得积分10
3秒前
辛勤的小海豚完成签到,获得积分10
7秒前
hang发布了新的文献求助10
8秒前
沈霸霸发布了新的文献求助10
8秒前
JJ完成签到,获得积分10
9秒前
萧水白应助前进的光采纳,获得10
10秒前
现实的小熊猫应助炜wei采纳,获得10
10秒前
10秒前
细胞呵呵完成签到,获得积分10
11秒前
禾盒完成签到,获得积分10
11秒前
斯文败类应助机灵的千琴采纳,获得10
12秒前
愉快的宛儿完成签到,获得积分20
13秒前
MeOH拿桶接完成签到,获得积分10
13秒前
erhgbw完成签到,获得积分10
14秒前
15秒前
15秒前
李健应助尽快看看采纳,获得10
15秒前
伊丽莎白完成签到,获得积分10
15秒前
青岚发布了新的文献求助10
16秒前
xms完成签到,获得积分10
16秒前
16秒前
18秒前
18秒前
李一帆发布了新的文献求助10
19秒前
20秒前
月生发布了新的文献求助10
21秒前
今后应助诺之采纳,获得10
21秒前
21秒前
Abdurrahman发布了新的文献求助10
23秒前
科研通AI2S应助浅香千雪采纳,获得10
23秒前
23秒前
ccy应助浅香千雪采纳,获得10
23秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Semiconductor Process Reliability in Practice 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 500
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3233861
求助须知:如何正确求助?哪些是违规求助? 2880343
关于积分的说明 8214733
捐赠科研通 2547792
什么是DOI,文献DOI怎么找? 1377216
科研通“疑难数据库(出版商)”最低求助积分说明 647789
邀请新用户注册赠送积分活动 623213